Research programme: sustained release paclitaxel - BioSyntech
Alternative Names: PacligelLatest Information Update: 15 Jan 2022
At a glance
- Originator BioSyntech
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Prostate cancer